Allozyne, Inc.

Rjs Biologics

Medimmune Limited

Stephen McCraith

Kenneth H Grabstein

Natalie Winblade Nairn

Deepshikha Datta

Aijun Wang

Thomas Graddis

Andrea Wang

There is disclosed a compound, a pharmaceutical composition and a method of treatment using a pharmaceutical composition comprising a tethering moiety that is capable of binding to a macrophage migration inhibitory factor (MIF) polypeptide, optionally linked to a linker moiety and further covalently bound to a drug moiety or imaging agent. More specifically, there is disclosed a genus of affinity-tethering moieties covalently bound to a drug moiety or imaging agent either directly or optionally via a linker moiety to covalently link the tethering moiety to a drug moiety. Without being bound by theory, the disclosed pharmaceutical compounds are targeted to cancer cells or immune cells via an affinity-tethering moiety that hitch-hikes to or into its target cell while bound to endogenous MIF.

Pharmaceutical compounds targeted by MIF affinity-tethered moieties

The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.

Modified human interferon-beta polypeptides

Modified human interferon-&#x3b2; polypeptides

Growing community of inventors

Seattle, WA, United States of America

Stephen McCraith